Kestra Medical Technologies (NASDAQ:KMTS) Director Kevin Reilly Sells 2,932 Shares

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Director Kevin Reilly sold 2,932 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $25.13, for a total transaction of $73,681.16. Following the transaction, the director owned 5,368 shares of the company’s stock, valued at approximately $134,897.84. This represents a 35.33% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Down 2.1%

NASDAQ KMTS opened at $23.57 on Friday. Kestra Medical Technologies, Ltd. has a 1-year low of $17.34 and a 1-year high of $30.00. The company has a market capitalization of $1.38 billion, a price-to-earnings ratio of -9.74 and a beta of 0.62. The stock’s 50 day moving average is $25.42 and its two-hundred day moving average is $22.71. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). The company had revenue of $28.64 million during the quarter. Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%. Equities analysts forecast that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Oppenheimer began coverage on shares of Kestra Medical Technologies in a research report on Tuesday, July 21st. They set a “market perform” rating for the company. JPMorgan Chase & Co. began coverage on shares of Kestra Medical Technologies in a research note on Monday, August 10th. They set an “overweight” rating and a $30.00 price objective on the stock. Weiss Ratings lowered shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 31st. Wolfe Research set a $30.00 target price on shares of Kestra Medical Technologies in a research note on Wednesday, July 15th. Finally, BTIG Research reissued a “buy” rating and issued a $32.00 target price on shares of Kestra Medical Technologies in a report on Wednesday, September 2nd. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Kestra Medical Technologies presently has an average rating of “Hold” and a consensus price target of $28.14.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in KMTS. Russell Investments Group Ltd. lifted its position in Kestra Medical Technologies by 43.5% during the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock worth $41,000 after buying an additional 474 shares in the last quarter. BNP Paribas Financial Markets grew its stake in shares of Kestra Medical Technologies by 148.9% during the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after purchasing an additional 1,638 shares during the last quarter. Daiwa Securities Group Inc. bought a new position in Kestra Medical Technologies in the 4th quarter worth approximately $72,000. Brown Brothers Harriman & Co. boosted its position in Kestra Medical Technologies by 26.8% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after buying an additional 656 shares during the last quarter. Finally, New York State Common Retirement Fund acquired a new stake in shares of Kestra Medical Technologies in the 2nd quarter valued at $93,000.

Key Stories Impacting Kestra Medical Technologies

Here are the key news stories impacting Kestra Medical Technologies this week:

• Positive Sentiment: Kestra appointed Daniel Finney as Vice President of Research & Development and added him to the executive leadership team. Finney has more than 20 years of Class III medical-device experience and previously led Kestra’s new product development efforts. He will oversee innovation for the Cardiac Recovery System platform, including strategic partnerships and artificial-intelligence initiatives. Kestra Names Daniel Finney Vice President of Research & Development
• Neutral Sentiment: Reported short interest was zero shares as of September 10, indicating no measurable short-selling pressure based on the filing data. However, the figure provides little incremental insight because it was also reported as zero in the prior period.
• Negative Sentiment: Four directors disclosed sales totaling about 16,424 shares worth approximately $414,000. The transactions reduced their individual holdings by roughly 9% to 48%. All four sales were explicitly made to cover tax-withholding obligations tied to vested equity awards, which makes them less bearish than discretionary open-market selling, but the cluster of transactions may still pressure sentiment. SEC insider transaction filing
• Negative Sentiment: Kestra’s latest reported quarter included an adjusted loss of $0.67 per share, worse than the $0.59 analyst consensus, alongside $28.64 million in revenue. The company remains unprofitable, increasing investor sensitivity to execution, product adoption and commercialization risks.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.